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Abstract Recent research has demonstrated how anti-
retrovirals (ARVs) could be effective in the prevention of
sexually transmitted HIV. We review research on the
acceptability of oral pre-exposure prophylaxis (PrEP) and
treatment as prevention (TasP) for HIV prevention amongst
potential users. We consider with whom, where and in
what context this research has been conducted, how
acceptability has been approached, and what research gaps
remain. Findings from 33 studies show a lack of TasP
research, PrEP studies which have focused largely on men
who have sex with men (MSM) in a US context, and varied
measures of acceptability. In order to identify when, where
and for whom PrEP and TasP would be most appropriate
and effective, research is needed in five areas: acceptability
of TasP to people living with HIV; motivation for PrEP use
and adherence; current perceptions and management of
risk; the impact of broader social and structural factors; and
consistent definition and operationalisation of acceptability
which moves beyond adherence.
Resumen Investigaciones recientes han demostrado la
forma en que los antirretrovirales pueden ser efectivos en la
prevencio´n del VIH. En este estudio se revisan trabajos
sobre la aceptacio´n de la profilaxis pre-exposicio´n (PrEP,
por sus siglas en ingle´s) y del tratamiento como prevencio´n
(TasP) para la prevencio´n del VIH entre los potenciales
usuarios. Tambie´n se consideran con quie´n, do´nde y en que´
contexto esos trabajos de investigacio´n han sido llevados a
cabo, co´mo se ha medido el nivel de aceptacio´n y cua´les
brechas de investigacio´n permanecen abiertas. Los
resultados de los 33 estudios considerados evidencian una
falta de investigacio´n en el campo de TasP y PrEP. En el
caso de estos u´ltimos, los estudios existentes se han enfo-
cado en hombres que tienen sexo con hombres en el con-
texto de los EEUU. Estos resultados tambie´n evidencian
una falta de investigacio´n en cuanto a las diferentes med-
idas de aceptacio´n. Con el objetivo de identificar cua´ndo,
do´nde y para quie´n PrEP y TasP serı´an ma´s apropiados y
efectivos, se requieren estudios adicionales en cinco a´reas:
la exploracio´n de la aceptabilidad de TasP para personas
que viven con VIH; desde el punto de vista motivacional
sobre el uso y adherencia a PrEP;; acerca de la forma actual
en la que se percibe y se maneja el riesgo; el estudio de
factores sociales y estructurales ma´s amplios; y por u´ltimo
sobre la consistencia en la definicio´n y sobre el fomento de
la aceptabilidad ma´s alla´ de la adherencia.
Keywords Pre-exposure prophylaxis  Treatment
as prevention  Acceptability  HIV prevention
Introduction
The 30 years of the HIV epidemic have been marked by
significant successes and failures in biomedical and
behavioural research. While a cure or vaccine remain
elusive, there have been significant advances in the clinical
treatment of HIV [1], the prevention of mother to child
transmission [2], and, to a lesser extent, in post-exposure
prophylaxis (PEP) [3]. There have also been important
community-based advocacy efforts and responses to HIV,
including safer sex and risk reduction strategies, which
form the basis of behavioural interventions as well as
provide better understandings of the social contexts of the
epidemic [4, 5]. However, the response to recent clinical
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trial results such as HPTN 052, Pre-exposure Prophylaxis
Initiative (iPrEx) trial, and Partners in Prevention, which
use antiretrovirals (ARVS) for prevention, has been sig-
nificant. Hailed as ‘the beginning of the end of AIDS’ [6],
these biomedical developments in HIV prevention provide
exciting, if challenging, opportunities for HIV prevention.
Pre-exposure prophylaxis (PrEP) is the use of ARVs by
HIV-negative individuals before potential exposure to HIV
to prevent transmission. The iPrEx trial examined the
efficacy of oral PrEP amongst men who have sex with men
(MSM) and transgender women at high-risk of HIV,
including HIV negative sexual partners in sero-discordant
relationships. A sub-study of the iPrEx trial found that a
daily dose of oral PrEP could reduce the risk of HIV
transmission by up to 99 % if adherence was high (taking
seven tablets or more per week) [7]. In the United States
(US), findings from iPrEx and other PrEP trials [8] resulted
in the US Food and Drug Administration (FDA) approval
of Truvada (emtricitabine/tenofovir disoproxil fumarate)
for use as PrEP in July 2012 [9]. This was coupled with the
release of Center for Disease Control and Prevention
(CDC) interim guidelines on PrEP use for both MSM in
January 2011 [10] and heterosexual men and women in
serodiscordant relationships in August 2012 [11]. The
guidelines advise initial screening for HIV and STIs,
ongoing adherence and condom counselling, and 2–3
monthly follow up that includes regular screening for HIV
and STIs. However, there have been mixed results from
major PrEP trials; studies such as FEM-PrEP and VOICE
recently failed to prove the effectiveness of PrEP as a result
of poor participant adherence to the drug regime [12]. The
US currently remains the only country where ARVs are
licensed for use as PrEP. While some countries such as
Latvia [13] have reported using PrEP, and HIV clinicians
in South Africa have issued guidelines for off-label use for
MSM, official implementation has been met with some
caution. For instance, the British HIV Association (BHI-
VA) and British Association for Sexual Health and HIV
(BASHH) issued a position statement calling for further
research to confirm whether PrEP should be used as an
effective HIV prevention option in the UK [14] and the
European Medicines Agency (EMA) recently held a con-
sultation on the clinical and non-clinical developments of
PrEP in Europe [15].
Treatment as Prevention (TasP), already used effectively to
prevent mother to child transmission [2], is also being advo-
cated as a means to manage and reduce sexual transmission of
HIV. The HPTN 052 trial found that starting HIV-positive
sexual partners on ARVs early (i.e. before their CD4 count
dropped below the levels of 200–350 cells/lL advised in
international guidelines for treatment initiation at the time of
the trial) resulted in a 96 % reduction in HIV transmission
amongst heterosexual serodiscordant couples [16]. The results
from HPTN 052 have led to changes in treatment guidelines in
the US and a number of European countries such as the UK,
France and Germany [13, 17, 18]. More recently, the World
Health Organisation has called for HIV treatment to be started
at 500 cells/lL [19]. These changes highlight how TasP is
rapidly establishing itself as a clinically sanctioned method of
HIV prevention [20]. However, although hailed as ‘proof of
concept’ in relation to ARVs preventing sexual transmission,
how TasP should be implemented on population-wide level is
less clear and has raised a number of practical and ethical
issues [21]. The effectiveness of TasP will rely on the early
diagnosis and retention in care of HIV positive individuals,
who often experience multiple barriers to accessing services
and treatment [22]. This approach also raises the question of
whether individuals living with HIV should be asked to start
treatment in order to prevent transmission to others, rather
than in relation to their clinical needs [23]. These issues need
to be addressed before TasP is rolled out at a population level.
Recent findings from PrEP and TasP trials are situated in
a longer history of how ARVs are part of and affect HIV
prevention. The introduction of highly active antiretroviral
therapy (HAART) in the mid-1990s raised concerns that
optimism as a result of new HIV treatment might result in
an increase in sexual risk behaviour. Research into HIV
treatment optimism did not find a consistent association
between HIV optimism and high-risk sexual behaviour
[24, 25]. More recently, a review of treatment-related
optimistic beliefs and risk of HIV transmission found
mixed results. While quantitative studies demonstrated a
link between optimism and risk of transmission, the review
found that inconsistent measures and qualitative findings
raise questions about this association and calls for a more
comprehensive examination of HIV treatment optimism
issues [26]. In 2008, the ‘Swiss Statement’ further com-
plicated HIV prevention messages by stating that people
living with HIV who are on treatment, have an viral load
that has been undetectable for at least 6 months and do not
have an STI are not sexually infectious [27]. Research
about issues raised by the Swiss Statement revealed that
sexual decision making in relation to HIV prevention was
not based solely on calculations of risk, but also on socio-
economic factors [28] and emotional and relationship pri-
orities [29]. These findings suggest that the way in which
people understand biomedical prevention methods and
incorporate them into the context of their everyday lives will
be critical to of the management of HIV-related risks.
There is considerable debate about the ways in which the
PrEP and TasP should (and will) be introduced as HIV pre-
vention options. Nguyen et al. [23] have expressed anxieties
that ARV prevention will replace behavioural interventions
(and the necessary funding of the latter); Padian et al. [1]
have called for combination prevention, recognizing the
continued need to manage and support behaviour change
196 AIDS Behav (2014) 18:195–216
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strategies [30]; and the VOICE trial findings have resulted in
calls for improved understandings of what social, cultural
and other factors affect adherence [31]. Indeed, rather than
separating biomedical from behavioural interventions, a
number of authors have characterised PrEP and TasP as bio-
behavioural, pointing to how individuals will have to modify
their behaviour to take the medication [32, 33]. As in the case
of HIV treatment optimism, responses to the Swiss State-
ment, and the non-adherence to PrEP by participants in the
VOICE trial, people’s actual use (or non-use) of PrEP or
TasP will have a significant impact on their effectiveness in
preventing the sexual transmission of HIV. We need,
therefore, to better understand if, how and in what contexts,
PrEP and TasP will be acceptable to people seeking to pre-
vent the sexual transmission of HIV.
While PrEP and TasP may reflect different program-
matic approaches to the prevention of sexual transmission
of HIV—an individual approach to PrEP in contrast to a
potential population-wide approach for TasP—there is
considerable overlap in how each intervention may be
managed at an individual level and how they may or may
not be acceptable to trial participants, potential end users
and/or their sexual partners. Research on the acceptability
of contraception, perhaps the closest comparator for bio-
medical-based interventions in sexual health, considers
acceptability to be the voluntary, sustained use of a product
in the context of alternatives [34]. With regards to oral and
microbicide-based PrEP in clinical trials, Mensch and
colleagues point out that there is little agreement in the
literature on how acceptability is defined and measured.
They suggest that acceptability should be judged in relation
to adherence to the medication, and consider elements such
as product attributes, dosing regimen, deliver mechanisms,
but also partner’s attitudes and the effects of the product on
sexual encounters [35]. Similarly, Golub et al. [33]
describe the need to support individuals in their uptake, use
and risk-reduction strategies, encouraging them to make
rational choices about their sexual health. In this review,
we assess the literature on the acceptability of oral PrEP
and TasP for the prevention of sexually transmitted HIV
amongst potential users. We consider with whom, where
and in what context this research has been conducted, how
acceptability has been approached, and what research gaps
remain.
Methods
Five major databases (Medline, Psychinfo, Web of Sci-
ence, Embase and Global Health) were initially searched
using the terms in Box 1. Subsequent searches were con-
ducted on PubMed to update the initial search. Articles
were included if they:
• examined acceptability of oral PrEP and/or TasP as HIV
prevention options in the context of sexual transmission;
• described primary data collection with current or potential
oral PrEP or TasP users (including empirical studies,
embedded studies in larger RCTs and process evaluations);
• were published in English; and
• were published between January 2008 (in order to
capture research related to recent ARV developments)
up to December 2012.
The earliest study identified in our search on the use of oral
ARV-based technologies for the prevention of sexually
transmitted HIV was published in 2008 and reflects the start-
point for this review. Editorials or comment pieces were
excluded as they did not include primary data collection. Of a
total of 90 articles found, 33 met the inclusion criteria. These
articles were all sourced from peer-reviewed journals. A
number of conference abstracts were identified, but were
excluded due to insufficient information about how accept-
ability was measured and limited information on findings.
Formal quality appraisal of the publications was not under-
taken as the aim of this review was to establish a broad
overview of research available, including how acceptability
was assessed, where studies have been conducted, and what
the key findings were in relation to acceptability. Assessment
was made of individual articles, even when multiple articles
were from the same study. The first author identified key
characteristics of each study in accordance with STROBE
Box 1 Search terms used
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(Strengthening the Reporting of Observational studies in
Epidemiology) checklist [36]. This specifically included:
participants; setting; type of intervention; study aims; study
design and methods; study size; measures of acceptability;
key results; and interpretations. The second author reviewed
the identification and organisation of key characteristics and
verified these findings.
Results
Of the 33 articles and reports in our review, 30 addressed
the acceptability of PrEP, reflecting 27 separate studies,
and three addressed the acceptability of TasP. A detailed
overview of each publication is included in Table 1.
PrEP Studies
Eight articles were based on non-clinical research embed-
ded in six separate larger clinical PrEP trials. Three arti-
cles, from two trials, focused on heterosexual women’s
experiences in serodiscordant relationships in African
countries [37–39], with an additional article focusing on
heterosexual women’s experiences in South Africa,
Uganda and the US [40]. Two articles from one trial in
Kenya explored acceptability and willingness amongst
MSM [41, 42] while one article focused on MSM in the US
[43]. The eighth article described the identification,
development and implementation of procedures within the
iPrEx study that intended to improve product use and self-
report across all the trial sites [44].
Twenty-two PrEP articles were from non-clinical trial
research and the majority of these focused on MSM. Ten
articles, from nine studies, were with MSM in the US
[45–54]. Other articles focusing on MSM included research
from the UK [55], Canada [56], France [57], Australia
[58, 59], Thailand [60], and China [61, 62]. Galea et al. [63]
focused on MSM, female sex workers, and transgendered
people in South America (Peru), as did Eisingerich et al. [64],
who also included intravenous drug users, serodiscordant
couples and young women in Ukraine, India and four
countries in Africa. Only two (US) studies explored attitudes
towards PrEP amongst heterosexual men and women
[65, 66]. The majority of these studies focused on daily oral
PrEP, with only five exploring attitudes towards intermittent, or
in some cases topical, PrEP use [57, 59, 60, 63, 64] (Table 2).
TasP Studies
Two of the three TasP studies were conducted in the US
[67, 68], and the other was Australian [69]. One explored
acceptability of TasP amongst people living with HIV but
not currently on treatment in Seattle, Washington [67]. A
second article examined beliefs around undetectable viral
loads and STI acquisition amongst men, women and
transgendered people living with HIV in Atlanta, Georgia
[68]. A third study explored attitudes towards ARVs, HIV
treatment and ARV-based prevention amongst both HIV-
positive and HIV-negative participants in Australia [69].
Measures of Acceptability
The articles used a range of approaches to assess and/or
measure acceptability of either PrEP or TasP. PrEP accept-
ability research embedded within RCTs used individual
adherence rates as a measure of acceptability. For those PrEP
studies outside of clinical research, the measurement and/or
assessment of acceptability varied greatly. Four articles
reported on willingness to use PrEP [45, 54–56]. Eight arti-
cles reported further on multiple attitudinal issues such as
willingness to take PrEP, HIV prevention, access to PrEP,
perceptions of personal risk, stigma and continued condom
use [48, 49, 51, 57, 58, 61, 62, 64, 65]. Two of these reported
on scenarios or conjoint analysis [51, 64]. Qualitative-based
articles were less specific about particular questions, but
reported a wide range of acceptability issues, including:
perceptions of transmission risk; feelings about safer sex;
information desired about PrEP; concerns with cost, access,
side-effects and regular testing [46, 47, 53, 63]. Measure-
ments of TasP acceptability were similar in variation. Two
studies reported on interest in TasP [67, 68]. One study
reported on scepticism that reduced viral loads would pre-
vent HIV, as well as concerns about side-effects, ease of
taking medication and stigma-related issues [69].
Although two studies [53, 66] highlighted the impor-
tance of how information regarding biomedical interven-
tions is framed and delivered to communities, few of the
articles reported on how they explained PrEP or TasP
efficacy to participants. Five articles presented PrEP effi-
cacy rates to participants of 80 % [48], 90 % [46, 47], or a
range of scenarios between 75 and 95 % efficacy [63], and
50 and 75 % efficacy [66]. However, the majority of
studies did not specify efficacy of PrEP to participants, or
did not report doing so. Similarly, TasP studies did not
present precise information about the efficacy of the
intervention. Participants in the study by Dombrowski et al.
[67] were told that they were less likely to transmit HIV
while on medication, but that no one knew for certain. Two
more TasP studies did not present participants with infor-
mation about TasP but asked a range of questions to gauge
beliefs about HIV medicines and infectiousness [68, 69].
Adherence as Acceptability
Three of the PrEP studies in clinical trials reported high
levels of adherence to daily pills, ranging from 82 to
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93 % [38, 40, 42]. However, Amico et al. [70] noted
discrepancies between self-report and actual adherence
rates in their needs assessment of adherence reporting in
the iPrEx trial. They described the way social stigma
played an important role in how adherence was reported;
the combination of pill monitoring and adherence coun-
selling did not provide the space for participants to
explore their adherence difficulties without feeling
judged. In the Partners in Prevention trial in Uganda,
participants’ adherence was significantly affected by a
desire to do no harm to their partner, and by the marital,
family and economic circumstances of the positive
partner [39].
Willingness as Acceptability
Studies that were not part of larger PrEP clinical research
trials reported limited knowledge of PrEP, ranging from
11 % [56] to 23 % [33]. One study [54] did report 62 % of
participants had heard of PrEP, although one-quarter mis-
took PEP for PrEP. Levels of willingness to use PrEP
ranged from 28 % [58] to 80 % [47]; eight out of eleven
studies offering numerical findings reported willingness
levels of 50 % or more [47–49, 51, 55, 56, 62, 64]. All of
the studies reporting willingness in this way focused on
MSM. Factors associated with willingness to use PrEP
were mixed and there were no strong similarities across the
studies. Greater willingness was associated in some studies
with lower levels of education [51] and younger age
[45, 55]. Four studies reported an association between
willingness to take PrEP and unprotected anal intercourse
(UAI) [49, 54–56], while Zhou et al. [62] reported an
association between PrEP willingness and inconsistent
condom use. However, Golub et al. [33] found no associ-
ation between willingness and age, income or education,
and Barash and Golden [45] found no association between
willingness and risk behaviour. Holt et al. [58] were unu-
sual in reporting low rates of willingness in their Australian
study. Factors associated with willingness in this study
were younger age, UAI with casual partners, and increased
risk-perceptions. Despite relatively high willingness to take
PrEP in most studies, anxieties around medication side-
effects were also commonly reported [46, 52, 63, 64]. Only
two studies explored associations with PEP experience and
none explored knowledge of and/or experience with earlier
generations of ARVs [50, 55].
In the TasP studies, knowledge of this prevention
method was low. In one, 56 % of HIV positive participants
expressed an interest in starting treatment early, while
61 % of participants felt doctors should offer early ART as
an option to prevent onward HIV transmission [67].
Interest in starting treatment in this study was associated
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MSM in Australia were sceptical that TasP could reduce
onward transmission risks, although HIV-positive partici-
pants were less sceptical than HIV-negative participants.
Risk Compensation and Disinhibition
Much of the research addressed the use of condoms and
sexual risk behaviour in combination with PrEP or TasP in
some capacity. Where reported, studies embedded in RCTs
described ongoing or even increased condom use in com-
bination with PrEP use amongst participants [38]. Outside
clinical trials, where PrEP was not yet available, studies
could only investigate hypothetical condom use and two
with MSM found that significant numbers of participants
predicted decreased condom use if PrEP were to be taken
[47, 63]. However, other studies with MSM predicted a
minimal decrease in condom use [48, 58, 62]. One study
described conflicting concerns amongst MSM that PrEP
could encourage UAI or could provide an additional safety
measure if condoms were not used [52]. One of the TasP
studies reported how participants took viral load into
account in relation to sexual risk and that having a low
viral load was associated with recent STI acquisition [68].
The authors suggested that beliefs around infectiousness
and increased risk of STI acquisition need to be addressed.
Few of the studies explored if, or how, participants
thought they were at risk. Four studies explicitly asked
about self-perceptions of risk [49, 53, 58, 65]. Of these, all
but one found most participants did not perceive them-
selves to be at high risk of HIV [53]. Studies that included
participants in serodiscordant relationships did not explic-
itly explore perceptions of risk. Brooks et al. [46] did
explore how serodiscordant MSM couples managed risk
and found that most relied on condoms, although strategic
positioning and withdrawal were also reported. Golub et al.
[48] reported that PrEP could reduce perceptions of HIV
risk amongst MSM who would see unprotected sex as an
acceptable risk in the context of PrEP (risk compensation),
but also reduce the behavioural constraints for men who
desire condomless sex (behavioural disinhibition). This
distinction between compensation and disinhibition was
only explored within a few studies. In addition, both Golub
et al. [48] and Holt et al. [58] found that some MSM who
reported non-condom use and high risk sexual behaviour
also indicated a willingness to use PrEP. The authors
concluded that non-condom use for these men may not be
risk compensation (the replacement of condoms with
PrEP); PrEP use would instead signal an increase in
response to risk of HIV because condoms were never or
rarely used.
Social and Structural Issues
Social and structural influences on adherence or willing-
ness were only considered by seven studies. Amico et al.
[70] demonstrated how social desirability to be an adherent
trial participant may play in both the reporting and man-
agement of PrEP adherence. Ware et al. [39] described how
the social context, especially in relation to intimate and/or
marital relationships, was integral to adherence as well as
to how HIV risk management is negotiated on a personal,
intra-personal and socio-cultural level. Looking to a
broader social context, Galindo et al. [53] reported on the
importance of awareness and understanding of PrEP within
communities and the need to address mistrust of medical
settings. Guest et al. [38] found that in addition to indi-
vidual counselling, structural constraints such as financial
concerns, access to health services and HIV-related social
Table 2 Breakdown of PrEP
articles by participants and
setting
a Galindo et al. [53] also
include TG participants
b Galea et al. [63] also include
TG and female sex worker
participants
c Smith et al. [66] also include
small number of MSM
participants




Clinical trial PrEP research
Heterosexual women Africa 4 3
Men who have sex with men (MSM) Africa 2 1
MSM US 1 1
Heterosexual and MSM Multi-country 1 1
Total 8 6
Non-Clinical trial PrEP research
MSMa US 10 9
MSM UK, Canada, France, Australia 5 5
MSMb China, Thailand, Peru 4 4
Serodiscordant Couples (SDC)
MSM and Transgender (TG)
Multi-country studies 1 1
Heterosexual men and womenc US 2 2
Total 22 21
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stigma needed to be considered when assessing and
responding to adherence challenges. Similarly, Galea et al.
[63] identified structural barriers to PrEP access and
adherence, such as cost of PrEP, mistrust of health pro-
viders and discrimination in relation to PrEP use. Where
Smith et al. [66] reported on the importance of low cost in
relation to willingness, and Galindo et al. [53] reported cost
as a significant barrier, Eisingerich et al. [64] found that
cost itself was not always a barrier as participants were
willing to pay for PrEP.
Discussion
This review found that acceptability research in relation to
PrEP and TasP was highly unbalanced in terms of popu-
lation, geographic diversity, and research context. Notably,
we found only three TasP acceptability studies and PrEP
acceptability research which focused primarily on MSM in
a US context. We also found varied accounts of accept-
ability and little reporting or consistency of how inter-
ventions were presented to participants. While levels of
willingness to use PrEP were high amongst the majority of
study participants, little attention was given to the impor-
tance of risk perception, as well as to how social and
structural influences would impact PrEP or TasP accept-
ability. Our findings have important implications for future
research, intervention implementation and scale-up. First,
we will discuss the limitations of this study.
We considered only peer review published studies.
Although a number of research gaps have been identified, this
is a fast moving field and the review may have missed other
studies have not yet been published in peer review journals.
We did not conduct a critical appraisal of study quality.
However, the aim of the study was to gain a broad overview of
the research available, rather than assess the quality. Finally,
this review focused primarily on research relating to oral
PrEP. Literature on the use of microbicides was not explored
and may have produced different evidence on awareness,
willingness and acceptability with different populations.
The sheer lack of TasP acceptability research demon-
strates that it has been framed primarily as a clinical and
health service delivery issue and tacitly assumes that peo-
ple living with HIV will accept early treatment as an
inevitability. Chen [26] reviewed research that explored the
impact of treatment-related optimistic beliefs and risk of
HIV transmission. However, this review focuses largely on
the understandings of science and potential for risk com-
pensation, rather than on the acceptability of using ARVs
as a clinically-endorsed HIV prevention intervention at the
point of diagnosis. Therefore, how people living with HIV
might negotiate both their epidemiological and social role
in HIV prevention, what additional burdens this might
place on their physical and mental health, and how TasP as
an intervention may play a role in reinforcing or refocusing
social stigma around HIV onto the positive body is largely
absent from the current scientific evidence.
The majority of PrEP research within trials focused on
heterosexual women in serodiscordant couples, while most
stand-alone studies concentrated almost exclusively on
MSM. There were only two studies which included heter-
osexual men. It is noteworthy that willingness to use PrEP
was reported to be high among MSM, suggesting it could
be a popular HIV prevention method within this popula-
tion. However, it is unclear why this may be the case.
Knowledge and willingness in some studies were associ-
ated with education and age, but there were no overall
consistent findings across studies. Age may still be an
important factor to explore, although it is unclear whether
there may be a generational effect. Future research should
consider how knowledge of and/or previous experiences
with HIV, particularly in relation to PEP [55], could
influence PrEP use. Most studies were conducted in the US,
and there was only one published articled on PrEP
acceptability in the UK with any population at the time of
the review. While there is research underway to address the
imbalance, this has implications for considering where, and
for whom, ARVs might offer a potential HIV prevention
option.
This review found highly varied measures of accept-
ability, which makes it difficult to compare results across
studies. This variation is supported by findings from
Mensch et al. [35] who highlight that there is little con-
sensus on the definition and operationalisation of accept-
ability for PrEP. However, different approaches to
acceptability did not appear to affect the overall results in
this review: the majority of studies reported high rates of
willingness to use PrEP, regardless of whether participants
were presented with a single willingness question, multiple
questions or a range of PrEP scenarios. This suggests the
need to further consider who is being asked about accept-
ability, how they respond to these questions and what
motivates these responses. For instance, motivation to take
or maintain adherence to PrEP may be affected by sero-
discordant relationships [39] or engagement in high-risk
sexual activity [48]. Questions about acceptability there-
fore need to push beyond simple willingness, to understand
the context within which interventions such as PrEP might
be acceptable and/or preferred. Only five studies provided
specific information, including efficacy rates, for PrEP,
whereas most did not specify these rates or did not report
this. Two articles described how this information, and the
way interventions are framed, will have significant impli-
cations for the acceptability and uptake of these interven-
tions [53, 66]. Transparency and consistency in terms of
how PrEP and TasP are presented to participants is
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therefore critical to understanding if, and in what circum-
stances, these interventions will be acceptable to potential
users, and how they might or might not be used in com-
bination with other prevention options. This will also
require consideration of the environment in which PrEP
and/or TasP are offered to potential users, including the
acceptability of these interventions to health practitioners
[71].
Acceptability was generally approached and assessed by
considering: willingness to take PrEP or TasP; adherence
to PrEP (or TasP); and subsequent or hypothetical risk
compensation and/or disinhibition. These approaches focus
on the ways in which the individual chooses and/or man-
ages the use of the intervention and their sexual behaviour
(hence their description as bio-behavioural) [32]. Although
important, willingness or adherence alone will not neces-
sarily translate into sustained and effective use of inter-
ventions; it is also critical to consider how individuals’
choices and actions are situated, constrained and/or enabled
by the broader social context [4]. There was limited evi-
dence of this in our review. Kippax and Stephenson [5]
have argued not only that the broader social context needs
to be considered, but that using ARVs for HIV prevention
will necessarily require understanding and responding to
the social context within which they might be used,
describing the need for a social public health approach. In
other words, the way in which individuals view, choose,
and maintain the use of particular HIV prevention methods
are significantly influenced by social, cultural and struc-
tural factors. Moreover, the social context within which
negotiations of safer sex take place will also have a real
impact on how interventions are sustained, and how sexual
behaviour may be modified in light of these new prevention
methods. This means that measurements of acceptability
will need to move beyond expressions of willingness or
adherence to medication, and consider the broader social,
cultural and structural factors that will impact and shape
the potential uptake and sustained effectiveness of PrEP
and/or TasP. While the evidence is limited in this review,
key factors include but are not limited to: social stigma,
social pressures regarding sexual relationships, mistrust of
medical settings and structural constraints including
financial barriers and access.
Perceptions of risk and choice of risk management
strategy appear to be key factors in adherence to PrEP [72].
However, risk perception and existing risk management by
participants were discussed in a minority of articles in our
review. As highlighted by Golub et al. [33] behavioural
disinhibition and risk compensation present important dif-
ferences in perceptions of risk and reasons for the choice
and/or apparent absence of particular HIV risk manage-
ment strategies. More nuanced understandings of risk
management, including how multiple and conflicting risks
might be managed, are therefore needed to better under-
stand in what circumstances PrEP may be an appropriate
intervention. In a community report which explored the
experiences of black Africans in serodiscordant relation-
ships living in the UK, Bourne et al. [73] described HIV
positive-women’s anxieties that TasP might reduce their
ability to negotiate condom use with discordant, male
partners. These women were reluctant to rely on TasP as a
prevention option, thus demonstrating how gender
dynamics in serodiscordant relationships can play an
important role in risk management strategies for HIV-
positive women. These issues highlight how complicated
social negotiations are embedded in starting and main-
taining adherence to ARV prevention methods. Future
acceptability research needs to consider the way in which
diverse social contexts will play a significant role in the
success of PrEP or TasP.
There was also limited evidence of the role structural
factors may play in the acceptability of biomedical pre-
vention. The studies that examined this suggested future
trial design and decisions about the introduction of bio-
medical prevention into sexual health services need to be
realistic about where adherence to PrEP is possible for
individuals and where more structural approaches to HIV
prevention may need to be pursued [38]. The need to
identify the causes of poor adherence was stressed. If social
structures form the biggest barriers to adherence, individual
counselling and support will be unable to improve adher-
ence rates. In addition, barriers such as access to health
services or the cost of interventions were identified as
playing an important role in the uptake of interventions.
However, the variation across studies in terms of national
and local health systems, and the extent to which cost was
identified as a barrier, makes it difficult to offer general
conclusions. This suggests the need to consider social and
structural elements specific to national and local contexts.
These findings echo Roberts and Matthews [74] who argue
for the importance of structural HIV prevention interven-
tions alongside biomedical and behavioural interventions.
Conclusions
Literature on the acceptability of ARV prevention inter-
ventions amongst potential users focused largely on MSM
(and to a lesser extent, heterosexual women in Africa), and
was strikingly limited when it came to TasP. In order to
strengthen understandings of how PrEP and/or TasP might
be introduced and maintained as sustainable and effective
HIV prevention interventions, further research is needed
in five areas: engagement with people living with HIV
in relation to potential TasP acceptability as well as per-
ceptions of existing experiences with ARVs; further
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operationalisation of measures of acceptability to enable
comparison between future studies and which move beyond
measurements of adherence alone; further examination of
what might motivate individuals to take PrEP, moving
beyond categories such as age and education; the role of
existing, complex (behavioural) risk management strategies
in the adoption of biomedical prevention; and the potential
role of social and structural influences above and beyond
individual choices and/or behaviours, which would include
examining the role of health providers in PrEP uptake and
support. These five broad areas of research would help to
further a social public health approach to acceptability and
enable the identification of when, where and for whom ARVs
for HIV prevention would be appropriate and effective. Our
review suggests that, despite the issuing of guidelines for
PrEP use in the US and the roll out of TasP at the clinical (if
not the population) level, numerous questions remain as to
just how acceptable, and therefore successful, these inter-
ventions will be in altering the course of the HIV epidemic.
We have a responsibility to ensure that they are answered to
achieve the true potential of biomedical HIV prevention.
Acknowledgments Funded by the UK Medical Research Council as
part of the Sexual Health programme (MC_A540_5TK60) at the
MRC/CSO Social and Public Health Sciences Unit, University of
Glasgow. Thanks to Candida Fenton, the Unit’s Information Scientist,
who conducted the original literature searches for the review.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr. Bio-
medical interventions to prevent HIV infection: evidence, chal-
lenges, and way forward. Lancet. 2008;372(9638):585–99.
2. Sturt Amy S, Dokubo Emily K, Sint Tin T. Antiretroviral therapy
(ART) for treating HIV infection in ART-eligible pregnant women.
Cochrane Database of Systematic Reviews. 2010. http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD008440/abstract. Accessed 2
Oct 2012.
3. Rey D. Post-exposure prophylaxis for HIV infection. Expert Rev
Anti Infect Ther. 2011;9(4):431–42.
4. Kippax S, Race K. Sustaining safe practice: twenty years on. Soc
Sci Med. 2003;57(1):1–12.
5. Kippax S, Stephenson N. Beyond the distinction between biomedical
and social dimensions of HIV prevention through the lens of a social
public health. Am J Public Health. 2012;102(5):789–99.
6. Havlir D, Beyrer C. The beginning of the end of AIDS? N Engl J
Med. 2012;367(8):685–7.
7. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir
concentrations and pre-exposure prophylaxis efficacy in men who
have sex with men. Sci Transl Med. 2012;4(151):1–8.
8. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-expo-
sure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Cochrane Database Syst Rev. 2012. http://onlinelibrary.wiley.
com/doi/10.1002/14651858.CD007189.pub3/abstract. Accessed 2
Oct 2012.
9. Food and Drug Administration (FDA). FDA approves first drug for
reducing the risk of sexually acquired HIV infection. Silver Spring,
MD: FDA. 2012. http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm312210.htm. Accessed 2 Oct 2012.
10. Center for Disease Control (CDC). Interim guidance: Pre-expo-
sure prophylaxis for the prevention of HIV infection in men who
have sex with men. Morbidity and Mortality Weekly Report.
2011;60(3):65–8.
11. Center for Disease Control (CDC). Interim guidance: pre-expo-
sure prophylaxis for the prevention of HIV infection in hetero-
sexually active adults. Morbidity and Mortality Weekly Report.
2012;61(31):586–9.
12. Rossi L. Daily HIV prevention approaches didn’t work for
African women in the VOICE study. Atlanta: MTN: Microbicides
Trials Network. 2013. http://www.mtnstopshiv.org/sites/default/
files/attachments/MTN_VOICE_Release_FINAL_.pdf. Accessed
8 May 2013.
13. ECDC. Thematic report: HIV treatment, care and support:
monitoring implementation of the Dublin Declaration on part-
nership to fight HIV/AIDS in Europe and central Asia: 2012
progress report. Stockholm: European Centre for Disease and
Prevention Control. 2013.
14. McCormack S, Fidler S, Fischer M. The British HIV Association/
British Association for Sexual Health and HIV position statement on
pre-exposure prophylaxis in the UK. Int J STD AIDS. 2012;23(1):1–4.
15. European Medicines Agency (EMA). Reflection paper on the
non-clinical and clinical development for oral and topical HIV
pre-exposure prophylaxis (PrEP). London: EMA. 2012. http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2012/03/WC500124054.pdf. Accessed 2 Oct 2012.
16. Cohen MS, McCauley M, Gamble TR. HIV treatment as pre-
vention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105.
17. BHIVA. BHIVA guidelines for the treatment of HIV-1 positive
adults with antiretroviral therapy 2012. London: British HIV
Association; 2012.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents: Department of Health and Human Ser-
vices, Office of AIDS Research Advisory Council (OARAC).
19. WHO. 2013. WHO issues new HIV recommendations calling for
earlier treatment. World Health Organisation. http://www.who.
int/mediacentre/news/releases/2013/new_hiv_recommendations_
20130630/en/index.html. Accessed 1 July 2013.
20. BHIVA, EAGA. Position statement on the use of antiretroviral
therapy to reduce HIV transmission January 2013, British HIV
Association (BHIVA) and the Expert Advisory Group on AIDS
(EAGA). HIV Med. 2013;14(5):259–62.
21. Williams BG, Lima V, Gouws E. Modelling the impact of anti-
retroviral therapy on the epidemic of HIV. Curr HIV Res. 2011;
9(6):367–82.
22. van de Laar MJ, Pharris A. Treatment as prevention: will it work?
Euro Surveillance. 2011;16(48):1–3.
23. Nguyen VK, Bajos N, Dubois-Arber F, O’Malley J, Pirkle CM.
Remedicalizing an epidemic: from HIV treatment as prevention
to HIV treatment is prevention. AIDS. 2011;25(3):291–3.
24. International Collaboration on HIV Optimism. HIV treatments
optimism among gay men: an international perspective. J Acquir
Immune Defic Syndr. 2003;32(5):545–50.
25. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy
and sexual risk behavior: a meta-analytic review. JAMA. 2004;
292(2):224–36.
26. Chen Y. Treatment-related optimistic beliefs and risk of HIV
transmission: a review of recent findings (2009–2012) in an era of
treatment as prevention. Curr HIV/AIDS Rep. 2013;10(1):79–88.
214 AIDS Behav (2014) 18:195–216
123
27. Vernazza PL. The debate continues: does ‘undetectable’ mean
‘uninfectious’? HIV Ther. 2009;3(2):113–6.
28. Rojas Castro D, Fugon L, Bourgeois-Fisson E, Le Gall JM,
Barbier F, Spire B. The ‘‘Swiss Statement’’: Who knows about it?
How do they know? What are its effects on people living with
HIV/AIDS? AIDS Care. 2012;24(8):1013–9.
29. Persson A. Reflections on the Swiss Consensus Statement in the
context of qualitative interviews with heterosexuals living with
HIV. AIDS Care. 2010;22(12):1487–92.
30. de Wit JBF, Aggleton P, Myers T, Crewe M. The rapidly
changing paradigm of HIV prevention: time to strengthen social
and behavioural approaches. Health Educ Res. 2011;26(3):
381–92.
31. Diallo DD. 2013. Coalition of U.S. Women’s health and HIV
advocates call for accelerated us government plan for demon-
strating feasibility of PrEP for women. Working Group on U.S.
Women and PrEP. http://www.avac.org/ht/a/GetDocumentAction/i/
49158. Accessed 1 July 2013.
32. Amico KR. Adherence to pre-exposure chemoprophylaxis: the
behavioral bridge from efficacy to effectiveness. Curr Opin HIV
AIDS. 2012;7(6):542–8.
33. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis
state of the science: empirical analogies for research and imple-
mentation. Curr HIV/AIDS Rep. 2010;7(4):201–9.
34. Severy LJ, Newcomer S. Critical issues in contraceptive and STI
acceptability research. J Soc Issues. 2005;61(1):45–65.
35. Mensch BS, van der Straten A, Katzen LL. Acceptability in
microbicide and PrEP trials: current status and a reconceptual-
ization. Curr Opin HIV AIDS. 2012;7(6):534–41.
36. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC. The
strengthening the reporting of observational studies in epidemi-
ology (STROBE) statement: guidelines for reporting observa-
tional studies. PLoS Med. 2007;4(10):e296.
37. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk
behavior among participants in a PrEP HIV prevention trial. Sex
Transm Infect. 2008;35(12):1002–8.
38. Guest G, Shattuck D, Johnson L, et al. Acceptability of PrEP for
HIV prevention among women at high risk for HIV. J Womens
Health. 2010;19(4):791–8.
39. Ware NC, Wyatt MA, Haberer JE, et al. What’s love got to do
with it? Explaining adherence to oral antiretroviral pre-exposure
prophylaxis for HIV-serodiscordant couples. J Acquir Immune
Defic Syndr. 2012;59(5):463–8.
40. Minnis AM, Gandham S, Richardson BA, et al. Adherence and
acceptability in MTN 001: a randomized cross-over trial of daily
oral and topical tenofovir for HIV prevention in women. AIDS
Behav. 2013;17(2):737–47.
41. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to
intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in Afri-
can men who have sex with men and female sex workers. PLoS
One. 2012;7(4):e33103.
42. Van der Elst EM, Mbogua J, Operario D, et al. High acceptability
of HIV pre-exposure prophylaxis but challenges in adherence and
use: qualitative insights from a phase I trial of intermittent and
daily PrEP in at-risk populations in Kenya. AIDS Behav.
2013;17(6):2162–72.
43. Hosek S, Siberry G, Bell M, et al. The acceptability and feasi-
bility of an HIV pre-exposure prophylaxis (PrEP) trial with young
men who have sex with men (YMSM). J Acquir Immune Defic
Syndr. 2012;62(4):447–56.
44. Amico KR, McMahan V, Goicochea P, et al. Supporting study
product use and accuracy in self-report in the iPrEx study: next
step counseling and neutral assessment. AIDS and Behavior.
2012;16(5):1243–59.
45. Barash EA, Golden M. Awareness and use of HIV pre-exposure
prophylaxis among attendees of a Seattle gay pride event and
sexually transmitted disease clinic. AIDS Patient Care STDs.
2010;24(11):689–91.
46. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ,
Leibowitz AA. Motivators, concerns, and barriers to adoption of
preexposure prophylaxis for HIV prevention among gay and
bisexual men in HIV-serodiscordant male relationships. AIDS
Care. 2011;23(9):1136–45.
47. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley
TW. Sexual risk behaviors and acceptability of HIV pre-exposure
prophylaxis among HIV-negative gay and bisexual men in sero-
discordant relationships: a mixed methods study. AIDS Patient
Care STDs. 2012;26(2):87–94.
48. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Pre-
exposure prophylaxis and predicted condom use among high-risk
men who have sex with men. J AIDS. 2010;54(5):548–55.
49. Krakower DS, Mimiaga MJ, Rosenberger JG, et al. Limited
awareness and low immediate uptake of pre-exposure prophy-
laxis among men who have sex with men using an internet social
networking site. PLoS One. 2012;7(3):e33119.
50. Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA,
Hudson SM. Preefficacy use and sharing of antiretroviral medi-
cations to prevent sexually-transmitted HIV infection among us
men who have sex with men. J AIDS. 2010;55(2):e14–6.
51. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Pre-
exposure antiretroviral prophylaxis attitudes in high-risk Boston
area men who report having sex with men: limited knowledge
and experience but potential for increased utilization after edu-
cation. J Acquir Immune Defic Syndr. 2009;50(1):77–83.
52. Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien
R. Knowledge and acceptability of alternative HIV prevention
bio-medical products among MSM who bareback. AIDS Care.
2008;20(1):106–15.
53. Galindo GR, Walker JJ, Hazelton P, et al. Community member
perspectives from transgender women and men who have sex
with men on pre-exposure prophylaxis as an HIV prevention
strategy: implications for implementation. Implement Sci.
2012;7(1):116.
54. Saberi P, Gamarel KE, Neilands TB, et al. Ambiguity, ambiva-
lence, and apprehensions of taking HIV-1 pre-exposure prophy-
laxis among male couples in San Francisco: a mixed methods
study. PLoS One. 2012;7(11):e50061.
55. Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone
A. Who would use PrEP? Factors associated with intention to use
among MSM in London: a community survey. Sex Transm
Infect. 2013;89(3):207–11.
56. Leonardi M, Lee E, Tan DH. Awareness of, usage of and will-
ingness to use HIV pre-exposure prophylaxis among men in
downtown Toronto, Canada. Int J STD AIDS. 2011;22(12):
738–41.
57. Lorente N, Fugon L, Carrieri MP, et al. Acceptability of an ‘‘on-
demand’’ pre-exposure HIV prophylaxis trial among men who
have sex with men living in France. AIDS Care. 2012;24(24):
468–77.
58. Holt M, Murphy DA, Callander D, et al. Willingness to use HIV
pre-exposure prophylaxis and the likelihood of decreased condom
use are both associated with unprotected anal intercourse and the
perceived likelihood of becoming HIV positive among Australian
gay and bisexual men. Sex Transm Infect. 2012;88(4):258–63.
59. Poynten IM, Jin F, Prestage GP, Kaldor JM, Imrie J, Grulich AE.
Attitudes towards new HIV biomedical prevention technologies
among a cohort of HIV-negative gay men in Sydney, Australia.
HIV Med. 2010;11(4):282–8.
60. van Griensven F, Thienkrua W, Sukwicha W, et al. Sex frequency
and sex planning among men who have sex with men in Bang-
kok, Thailand: implications for pre- and post-exposure prophy-
laxis against HIV infection. J Int AIDS Soc. 2010;13(13):1–14.
AIDS Behav (2014) 18:195–216 215
123
61. Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y.
Cognitive, psychosocial, and sociodemographic predictors of
willingness to use HIV pre-exposure prophylaxis among Chinese
men who have sex with men. AIDS Behav. 2012;16(7):1853–61.
62. Zhou F, Gao L, Li S, et al. Willingness to accept HIV pre-
exposure prophylaxis among Chinese men who have sex with
men. PLoS One. 2012;7(3):e32329.
63. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-
exposure prophylaxis as an HIV prevention strategy: Barriers and
facilitators to pre-exposure prophylaxis uptake among at-risk
Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.
64. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul
MR, Piot PK. Attitudes and acceptance of oral and parenteral
HIV preexposure prophylaxis among potential user groups: a
multinational study. PLoS One. 2012;7(1):e28238.
65. Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W.
Self-perceived risk of HIV infection and attitudes about pre-
exposure prophylaxis among sexually transmitted disease clinic
attendees in South Carolina. AIDS Patient Care STDs. 2011;
25(6):365–70.
66. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R.
Attitudes and program preferences of African–American urban
young adults about pre-exposure prophylaxis (PrEP). AIDS Educ
Prev. 2012;24(5):408–21.
67. Dombrowski JC, Harrington RD, Fleming M, Golden MR.
Treatment as prevention: are HIV clinic patients interested in
starting antiretroviral therapy to decrease HIV transmission?
AIDS Patient Care STDs. 2010;24(12):747–50.
68. Kalichman SC, Eaton L, Cherry C. Sexually transmitted infec-
tions and infectiousness beliefs among people living with HIV/
AIDS: implications for HIV treatment as prevention. HIV Med.
2010;11(8):502–9.
69. Holt M, Murphy D, Callander D, et al. HIV-negative and HIV-
positive gay men’s attitudes to medicines, HIV treatments and
antiretroviral-based prevention. AIDS Behav. 2012;17(6):2156–61.
70. Amico K, McMahan V, Goicochea P, et al. Supporting study product
use and accuracy in self-report in the iPrEx study: next step coun-
seling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.
71. Puro V, Palummieri A, de Carli G, Piselli P, Ippolito G. Attitudes
towards antiretroviral pre-exposure prophylaxis (PrEP) prescription
among HIV specialists. BMC Infect Dis. 2013;13(217):1–8.
72. Mascolini M. Tenofovir PrEP reduces HIV transmission risk by
up to 99%: adherence critical to protection from HIV in partners
PrEP trial of TDF and TDF/FTC 19th Conference on Retrovi-
ruses and Opportunistic Infections. Washington: Seattle; 2012.
73. Bourne A, Dodds C, Weatherburn P, et al. Plus one: HIV sero-
discordant relationships among black African people in England.
London: Sigma Research; 2011.
74. Roberts ET, Matthews DD. HIV and chemoprophylaxis, the
importance of considering social structures alongside biomedical
and behavioral intervention. Soc Sci Med. 2012;75(9):1555–61.
216 AIDS Behav (2014) 18:195–216
123
